Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Ot

Casey’s General Stores (CASY) reported fiscal Q4 EPS of $4.37, above analysts’ $3.31 forecast, on revenue of $4.57B versus $4.33B expected. The company cited 29% higher fuel gross profit and 5.5% same-store sales growth (vs 4.9% expected). Guidance for FY2027 calls for 2%–5% same-store sales growth and 8%–10% earnings growth.

Casey’s General Stores (NASDAQ: CASY) reported diluted EPS of $4.37, up 66.2% year over year, and beat analyst expectations, sending the stock up more than 20% in one session, according to the article. Fuel margin was $0.469 per gallon while retail fuel prices rose 14.1%. Inside sales grew 10.2% and annual net margin rose to 4.1% from 3.4%; management guided EBITDA growth of 8%–10%.

Casey’s General Stores shares rose 16.10% to $883.71 on Wednesday, after the company reported strong Q4 results, raised its dividend, and gave a positive outlook for fiscal 2027, according to the article. Net income increased 65.5% to $162.7M and EPS rose 66.2% to $4.37; revenue grew 14.5% to $4.57B. The company also expanded its $1B buyback authorization and lifted its quarterly dividend 14% to $0.65.

Casey’s General Stores (NASDAQ:CASY) shares rose 2.87% to about $783 after the company reported fiscal Q4 results. According to the report, Q4 EPS was $4.37 vs. $3.32 expected (+31.63%) and revenue was $4.57B vs. $4.35B (+5.06%). Net income rose 65.5% to $162.7M. For fiscal 2027, it expects EBITDA growth of 8%–10% and same-store sales up 2%–5%. UBS raised its price target to $805 from $706 and kept a Neutral rating.

CASEYS GENERAL STORES INC (CASY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 6 ex991q42026pressrelease.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Casey’s General Stores, Inc. One SE Convenience Blvd Ankeny, IA 50021 Casey's Announces Fourth Quarter and Fiscal Year Results Ankeny, IA, June 9, 2026 - Casey’s General Stores, Inc., ("Case

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.